BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1968094)

  • 1. HIV-1 neutralizing antibodies in urine from seropositive individuals.
    Cao YZ; Friedman-Kien AE; Mirabile M; Li XL; Alam M; Dieterich D; Ho DD
    J Acquir Immune Defic Syndr (1988); 1990; 3(3):195-9. PubMed ID: 1968094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
    Swiderska H; Kalinowska B
    Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific western blot bands are associated with initial CD4+ lymphocyte counts in human immunodeficiency virus seroconverters. The Navy HIV Working Group.
    Garland FC; Garland CF; Gorham ED; Brodine SK; Weiss PJ
    Ann Epidemiol; 1994 Jan; 4(1):27-31. PubMed ID: 7911377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation of secretory antibodies in parotid saliva to human immunodeficiency virus type 1 with HIV-1 disease stage.
    Sun D; Archibald DW; Furth PA
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):933-41. PubMed ID: 2117957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
    Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers.
    Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP
    J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
    Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
    Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
    Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
    Höglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B
    Viral Immunol; 1990; 3(3):195-206. PubMed ID: 2257052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.
    Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG
    J Clin Microbiol; 1994 Jun; 32(6):1449-56. PubMed ID: 8077388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ELISA-inhibition assay for antibody to human immunodeficiency virus core antigen (p24).
    Povolotsky J; Gold JW; Darminin P; Chein N; Baron P; Armstrong D
    J Virol Methods; 1990 Oct; 30(1):109-14. PubMed ID: 2128300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.
    Cavacini LA; Emes CL; Power J; Underdahl J; Goldstein R; Mayer K; Posner MR
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1093-102. PubMed ID: 7692037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy.
    Böttiger B; Morfeldt-Månson L; Putkonen P; Nilsson B; Julander I; Biberfeld G
    Scand J Infect Dis; 1989; 21(5):507-14. PubMed ID: 2511625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
    Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.